Evolus Expands Innovation Pipeline with Novel Injectable Hair Restoration Program
Evolus entered an option agreement with a privately held company developing a sustained-release injectable hair restoration treatment, giving it a path to a potential first-in-class aesthetic procedure. Evolus pays a $1.5 million initial option fee plus stage-gated payments, with the option — not the obligation — to acquire 100% of the program assets after an initial clinical proof-of-concept dataset.
Key figures
- Deal Value Usd
- $1.5 million initial option payment plus stage-gated milestone payments
- Initial option payment
- $1.5 million
- Formulation development through
- 2027
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.